Show simple item record

dc.contributor.author Ács, Balázs
dc.contributor.author Szarvas, Tibor
dc.contributor.author Szekely N
dc.contributor.author Nyirády, Péter
dc.contributor.author Szász, Attila Marcell
dc.date.accessioned 2016-08-09T18:50:29Z
dc.date.available 2016-08-09T18:50:29Z
dc.date.issued 2015
dc.identifier.citation pagination=643-651; journalVolume=15; journalIssueNumber=8; journalTitle=CURRENT CANCER DRUG TARGETS;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/2272
dc.description.abstract In this review we briefly discuss the possible biomarkers of prostate cancer among them we focus and analyze the relevance of TMPRSS2-ERG fusion gene in line with ERG expression in the diagnosis of prostate cancer. Starting at diagnosis and genetic alterations in prostate carcinomas, we examine the incidence and detection of the most common genetic aberration in this tumor and its protein product as well. We also examined the correlation of clinicopathological factors and prognosis with ERG and the TMPRSS2-ERG fusion oncogene and ERG expression as predictive markers.
dc.relation.ispartof urn:issn:1568-0096
dc.title Current State of ERG as Biomarker in Prostatic Adenocarcinoma.
dc.type Journal Article
dc.date.updated 2015-11-05T09:59:28Z
dc.language.rfc3066 en
dc.identifier.mtmt 2963888
dc.identifier.pubmed 26452381
dc.contributor.department SE/AOK/I/II. Sz. Patológiai Intézet
dc.contributor.department SE/AOK/K/Urológiai Klinika
dc.contributor.institution Semmelweis Egyetem


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account